• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
CardioVascular BioTherapeutics, Inc. (CVBT) - Financial and Strategic Analysis Review Product Image

CardioVascular BioTherapeutics, Inc. (CVBT) - Financial and Strategic Analysis Review

  • Published: August 2010
  • 25 pages
  • GlobalData

FEATURED COMPANIES

  • bioMerieux S.A.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GenVec, Inc.
  • Sanofi-Aventis
  • MORE

Cardiovascular Biotherapeutics, Inc. (CVBT) is a biopharmaceutical company. It is engaged in the development of protein drugs for the treatment of regenerative cardiovascular diseases. The company's development stage product facilitates the growth of new blood vessels in the heart, tissues and organs. Its primary product candidate FGF-1 (141), is designed to facilitate the growth of new blood vessels in the heart and other tissues and organs with an impaired vascular system and is currently undergoing Phase II clinical trials for treatment of coronary heart disease. The company is headquartered in Las Vegas, United States.

This comprehensive SWOT profile of CardioVascular BioTherapeutics, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including,

- READ MORE >



List of Tables
List of Figures
Section 1 - About the Company
CardioVascular BioTherapeutics, Inc. - Key Facts
CardioVascular BioTherapeutics, Inc. - Key Employees
CardioVascular BioTherapeutics, Inc. - Key Employee Biographies
CardioVascular BioTherapeutics, Inc. - Major Products and Services
CardioVascular BioTherapeutics, Inc. - History
CardioVascular BioTherapeutics, Inc. - Company Statement
CardioVascular BioTherapeutics, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
CardioVascular BioTherapeutics, Inc. - Business Description
CardioVascular BioTherapeutics, Inc. - SWOT Analysis
SWOT Analysis - Overview
CardioVascular BioTherapeutics, Inc. - Strengths
Strength - Agreements
Strength - Proprietary Technology
CardioVascular BioTherapeutics, Inc. - Weaknesses
Weakness - Dependence on Single Supplier
Weakness - Increased Presence of Debt
CardioVascular BioTherapeutics, Inc. - Opportunities
Opportunity - Marketing Strategy
Opportunity - Molecules in Clinical Development
Opportunity - Market Potential
CardioVascular BioTherapeutics, Inc. - Threats
Threat - Emergence of Biogenerics/Biosimilars
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Competition
CardioVascular BioTherapeutics, Inc. - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

F. Hoffmann-La Roche Ltd.
Genentech, Inc.
GenVec, Inc.
Boston Scientific Corporation
Ortho-Clinical Diagnostics Inc.
Dade Behring Holdings, Inc. (Inactive)
bioMerieux S.A.
Sanofi-Aventis

Note: Product cover images may vary from those shown

RELATED PRODUCTS